Matches in Wikidata for { <http://www.wikidata.org/entity/Q99956464> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- Q99956464 description "clinical trial" @default.
- Q99956464 description "ensayo clínico" @default.
- Q99956464 description "ensayu clínicu" @default.
- Q99956464 description "klinisch onderzoek" @default.
- Q99956464 description "клінічне випробування" @default.
- Q99956464 description "临床试验" @default.
- Q99956464 name "A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis" @default.
- Q99956464 name "A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis" @default.
- Q99956464 type Item @default.
- Q99956464 label "A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis" @default.
- Q99956464 label "A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis" @default.
- Q99956464 prefLabel "A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis" @default.
- Q99956464 prefLabel "A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis" @default.
- Q99956464 P1050 Q99956464-67F7BAC8-2739-4F4A-960E-85BFA2620324 @default.
- Q99956464 P1050 Q99956464-912B0583-92F0-4933-8925-8E6B703047C3 @default.
- Q99956464 P1050 Q99956464-C9387D3C-A7E6-4474-8610-D0CA910E0E62 @default.
- Q99956464 P1132 Q99956464-38131331-1274-4D19-AB89-AF0342745DC1 @default.
- Q99956464 P1476 Q99956464-29F0D6A5-BC8E-4BE2-8829-3512CF6B72A0 @default.
- Q99956464 P17 Q99956464-4D62DAA2-E4E0-45AD-BA30-448E9CE8C33F @default.
- Q99956464 P17 Q99956464-7115AD5B-340D-4390-839C-B012157C963C @default.
- Q99956464 P17 Q99956464-7DCF943C-2E51-4026-B433-9FBAA8B3BA68 @default.
- Q99956464 P17 Q99956464-85A7A1DE-7EEE-47E2-98B2-2C4033A0D20D @default.
- Q99956464 P17 Q99956464-A116FF0D-96EA-4EC6-B2BE-A89830F5F49E @default.
- Q99956464 P17 Q99956464-C69B0C9D-1892-4023-9092-D358846D78EA @default.
- Q99956464 P2899 Q99956464-CEB99615-7163-47E4-A378-FA896EB4AC2A @default.
- Q99956464 P3098 Q99956464-8E238C42-7EA1-4321-8812-ADA2DEBCDA49 @default.
- Q99956464 P31 Q99956464-947CA85B-8A38-4983-8A95-4AF66DE32682 @default.
- Q99956464 P4135 Q99956464-E251619D-D5C1-4058-9A38-EDA47D547E42 @default.
- Q99956464 P4844 Q99956464-5EEE8E56-A3C6-471E-8513-15111F1B546D @default.
- Q99956464 P4844 Q99956464-9797041A-6B41-413E-8B7F-6A362032FBFF @default.
- Q99956464 P580 Q99956464-7A82DD89-C7C9-4778-81CC-A2AA175841C2 @default.
- Q99956464 P582 Q99956464-8DA1637B-4089-4E0D-B150-FD392557BE25 @default.
- Q99956464 P6099 Q99956464-9255003B-2D8D-47A4-82C0-FF038B3054F6 @default.
- Q99956464 P6153 Q99956464-6ABFCE3C-43C6-464B-A58D-0051588753FA @default.
- Q99956464 P6153 Q99956464-DE95253E-AFB3-4489-9DD3-26906EDBBE95 @default.
- Q99956464 P6153 Q99956464-FC546B78-EE07-44ED-BE6E-418C8FEBD032 @default.
- Q99956464 P8005 Q99956464-9D98498C-98CF-408B-ADD9-3974EB73350F @default.
- Q99956464 P8363 Q99956464-ABEBB59F-AFB7-48B6-B659-6303156FEAB6 @default.
- Q99956464 P859 Q99956464-79160106-AF14-433B-A252-54543CCD6D02 @default.
- Q99956464 P1050 Q170990 @default.
- Q99956464 P1050 Q2165411 @default.
- Q99956464 P1050 Q52844 @default.
- Q99956464 P1132 "+100" @default.
- Q99956464 P1476 "Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis" @default.
- Q99956464 P17 Q142 @default.
- Q99956464 P17 Q145 @default.
- Q99956464 P17 Q183 @default.
- Q99956464 P17 Q29 @default.
- Q99956464 P17 Q31 @default.
- Q99956464 P17 Q38 @default.
- Q99956464 P2899 "+2" @default.
- Q99956464 P3098 "NCT04527380" @default.
- Q99956464 P31 Q30612 @default.
- Q99956464 P4135 "+17" @default.
- Q99956464 P4844 Q13574436 @default.
- Q99956464 P4844 Q348260 @default.
- Q99956464 P580 "2020-11-16T00:00:00Z" @default.
- Q99956464 P582 "2023-03-17T00:00:00Z" @default.
- Q99956464 P6099 Q42824827 @default.
- Q99956464 P6153 Q3145371 @default.
- Q99956464 P6153 Q4969002 @default.
- Q99956464 P6153 Q7492756 @default.
- Q99956464 P8005 Q76649614 @default.
- Q99956464 P8363 Q78089383 @default.
- Q99956464 P859 Q632240 @default.